Charlotta Liljebris
Directeur Technique/Scientifique/R&D chez XSPRAY PHARMA AB
Postes actifs de Charlotta Liljebris
Sociétés | Poste | Début | Fin |
---|---|---|---|
XSPRAY PHARMA AB | Directeur Technique/Scientifique/R&D | 01/01/2018 | - |
Liljebris Consulting Ab | Corporate Officer/Principal | - | - |
Historique de carrière de Charlotta Liljebris
Anciens postes connus de Charlotta Liljebris
Sociétés | Poste | Début | Fin |
---|---|---|---|
Connect Uppsala | Directeur/Membre du Conseil | - | - |
Recipharm OT Chemistry AB
Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The company is based in Uppsala, Sweden. | Directeur/Membre du Conseil | - | - |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | - | - |
SPRINT BIOSCIENCE AB | Directeur/Membre du Conseil | 01/01/2017 | - |
Independent Dir/Board Member | 01/01/2017 | - | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - | - |
Formation de Charlotta Liljebris
University of Uppsala | Doctorate Degree |
Statistiques
Internationale
Suède | 9 |
Opérationnelle
Corporate Officer/Principal | 3 |
Director/Board Member | 3 |
Independent Dir/Board Member | 1 |
Sectorielle
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
SPRINT BIOSCIENCE AB | Health Technology |
XSPRAY PHARMA AB | Health Technology |
Entreprise privées | 5 |
---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Recipharm OT Chemistry AB
Recipharm OT Chemistry AB Pharmaceuticals: MajorHealth Technology Part of Recipharm AB, Recipharm OT Chemistry AB develops and manufactures drug dosage forms and inhalation products & devices. The company is based in Uppsala, Sweden. | Health Technology |
Liljebris Consulting Ab | |
Connect Uppsala |
- Bourse
- Insiders
- Charlotta Liljebris
- Expérience